BACKGROUND: Kligman's triple combination formula has been one of the most popular treatment options in @entity1709 over the last three decades. The original Kligman's formula has been modified in many ways over the years and the most recent modification that has been introduced is a triple combination of 2% @entity8156 , 0.025% @entity1968 , and 1% @entity10438 . The use of this triple combination in @entity1 with @entity1709 has seen a sharp rise over the last few years and with this rampant use the side-effect profile of this triple combination has also come to the fore. AIM: The aim of the present study was to assess the overall safety of the @entity10438 -based triple combination treatment in the management of @entity1709 . MATERIALS AND METHODS: This retrospective study was performed on 60 @entity1 of @entity1709 who had used a @entity10438 -based triple combination treatment for at least 3 weeks anytime in the previous 1 year. The @entity1 were given a preformed questionnaire wherein they assessed the overall effect of the triple combination treatment on their @entity1709 during its use as well as after its withdrawal. The @entity1 were specifically asked about the status of their disease as well as the sun sensitivity of their skin before and after the use of triple combination treatment. In addition, the @entity1 were assessed by a single trained dermatologist for the presence of any adverse effects arising out of the triple combination treatment in the form of @entity8721 , @entity12737 , @entity5477 , @entity272 , etc. RESULTS: Majority of @entity1 (51.7%) had used the combination treatment well beyond the recommended duration. About one-third (36.7%) of the @entity1 rated their @entity1709 as worse at the time of filling the questionnaire as compared with their disease before the use of triple combination treatment. On clinical examination, the evidence of @entity134 side effects was seen in 26 @entity1 (43.3%). @entity134 -induced @entity8721 was the commonest finding, seen in all of these 26 @entity1 . @entity134 -induced @entity272 , @entity12737 , and @entity31351 were seen in 19, 17, and 11 @entity1 , respectively. CONCLUSIONS: The propensity of a @entity10438 -based triple combination treatment to cause @entity134 adverse effects on the facial skin should always be borne in mind when the same is prescribed as a treatment option in @entity1709 .

@entity10438 -based triple combination therapy in XXXX : is it really safe?

@entity1 :: ('9606', 'Species') :: ['patients'] @entity5477 :: ('MESH:D000152', 'Disease') :: ['acne'] @entity8721 :: ('MESH:D013684', 'Disease') :: ['telangiectasia'] @entity8156 :: ('MESH:C031927', 'Chemical') :: ['hydroquinone'] @entity31351 :: ('MESH:D017486', 'Disease') :: ['acneiform eruption'] @entity12737 :: ('MESH:D006983', 'Disease') :: ['hypertrichosis'] @entity134 :: ('CHEBI:35341', 'Chemical') :: ['Steroid', 'steroid'] @entity1968 :: ('MESH:D014212', 'Chemical') :: ['tretinoin'] @entity1709 :: ('MESH:D008548', 'Disease') :: ['melasma'] @entity272 :: ('MESH:D012871', 'Disease') :: ['skin atrophy'] @entity10438 :: ('MESH:C053915', 'Chemical') :: ['mometasone']
@entity1709 :: (MESH:D008548,Disease) :: ['melasma']
